Zoll launches 5th-gen wearable cardioverter defibrillator
December 19, 2025
Zoll announced today that it launched its next-generation LifeVest wearable cardioverter defibrillator (WCD) in the U.S.
Zoll announced today that it launched its next-generation LifeVest wearable cardioverter defibrillator (WCD) in the U.S.
GlucoModicum today unveiled Sofio, which it labels the world’s first needle-free glucose monitor based on magneto-hydrodynamics (MHD).
BONADUZ, Switzerland, Dec. 16, 2025 /PRNewswire/ — Hamilton today announced the launch of GlucoSense, a breakthrough in bioprocess analytics that introduces the first reusable, in situ glucose sensor designed to deliver continuous, real-time measurements directly inside cell culture bioreactors.
New production capacity strengthens MPM Medical’s position as a leading U.S. manufacturer and follows the company’s recent launch of collagen at-home wound care kits
IRVINE, Calif., Dec. 16, 2025 /PRNewswire/ — OrthAlign, Inc., a global leader in surgical navigation technologies, today announced the expansion of its Lantern® Hip platform to include support for posterior-based approaches in total hip arthroplasty (THA).
NEWPORT BEACH, Calif., Dec. 9, 2025 /PRNewswire/ — Medit, a global leader in 3D intraoral scanning and digital dentistry solutions, today announced the launch of AuraVue, a next-generation visualization and consultation platform that integrates Overjet’s AI technology to deliver real-time diagnostic insights and clearer patient communication.
TEL AVIV, Israel, Dec. 9, 2025 /PRNewswire/ — MedINT today announced the commercial launch of the first human-in-the-loop medical AI platform designed to return full control of evidence review and treatment decisions to clinicians managing complex patients. The system maintains clinician control at every step by delivering patient-specific evidence summaries that support clinical judgment without replacing it.
Partnership will expand Shoulder Innovations’ Disruptive Ecosystem with Advanced Enabling Technology, Complementing Surgeon and Patient Needs in the ASC
Three- and Four-Laser BD FACSDiscover A8 Cell Analysers Expand Accessibility of Spectral, Real-Time Imaging Cell Analysis
ST. PAUL, Minn., Dec. 3, 2025 /PRNewswire/ — Astrin Biosciences, a cancer intelligence company transforming how cancer is detected and treated through deep proteomics and AI, announced the launch of Certitude™, the first-of-its-kind, non-imaging, blood-based early cancer detection test. Results from the latest study will be presented at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place December 10–14, 2025.